嵌合抗原受体T细胞治疗实体瘤的研究进展和挑战  

Advances and challenges in the treatment of solid tumors with chimeric antigen receptor T cells

作　　者：闵静婷 李正红[1] Min Jingting;Li Zhenghong(Department of Pathophysiology,Bengbu Medical College,Anhui Bengbu 233030,China)

机构地区：[1]蚌埠医学院病理生理实验室,安徽蚌埠233030

出　　处：《现代肿瘤医学》2020年第18期3271-3275,共5页Journal of Modern Oncology

基　　金：国家自然科学基金(编号:81472656);安徽省重点研究和开发计划项目(编号:201904a07020019)。

摘　　要：随着嵌合抗原受体疗法在血液系统癌症中的惊人疗效,研究者们也在实体瘤方面展开探索。我们将回顾近年来嵌合抗原受体T细胞(CAR-T)治疗卵巢癌、肺癌、肝癌等实体瘤的研究进展;还将对CAR-T细胞治疗实体瘤的局限性,即抗原特异性问题、CAR-T细胞贩运问题以及肿瘤微环境问题结合相应对策进行综述。Researchers are also exploring solid tumors,following the impressive efficacy of chimeric antigen receptor therapy in cancers of the blood system.We will review the research progress of CAR-T cells in the treatment of ovarian cancer,lung cancer,liver cancer and other solid tumors in recent years.The limitations of CAR-T cell therapy for solid tumors,such as antigen specificity,CAR-T cell trafficking and tumor microenvironment,combined with corresponding countermeasures,also will be reviewed.

关 键 词：嵌合抗原受体T细胞 实体瘤 过继性免疫治疗 

分 类 号：R730.5[医药卫生—肿瘤]